Liu Yuxin, Shang Xiaoling, Wu Hongliang, He Ze
Basic Medical School, Changchun University of Chinese Medicine, Changchun 130117, China.
Vocational Education Teaching and Research Training Center, Jilin Provincial Institute of Education, Changchun 130117, China.
J Diabetes Res. 2024 Nov 26;2024:4180944. doi: 10.1155/jdr/4180944. eCollection 2024.
No comprehensive meta-analysis has evaluated the efficacy and safety of the protective effect of Jiedu Tongluo Therapy on the kidney of DKD until now. This meta-analysis covers this gap in knowledge. We have conducted an extensive search of databases, including CNKI, Wanfang, PubMed, and Web of Science. The selection was based on conventional treatment, including information and education on DKD, blood glucose, hypertension control methods, and lifestyle. The control group was composed of conventional western medicine or proprietary Chinese medicine, and the experimental group was composed of Jiedu Tongluo therapy controlled trials (RCTs) between 2003 and 2023. R 4.1.0 software was used to perform statistical analysis. A total of 1871 patients from 19 RCTs were analyzed. Meta-analysis results showed that the Jiedu Tongluo therapy was effective in improving clinical efficacy (OR = 2.47, 95% CI [1.94, 3.15], = 0%), and these trials were more effective in reducing Scr (MD = -19.81, 95% CI [-27.64, -11.97], < 0.01), BUN (MD = -0.70, 95% CI [-1.13, -0.27], < 0.01), UAER (MD = -29.97, 95% CI [-37.33, -22.61], < 0.01), FBG (MD = -0.85, 95% CI [-1.22, -0.47], < 0.01), and certain medication safety (OR = 0.75, 95% CI [0.27, 2.11]). For treating diabetic kidney disease, TCM-based Jiedu Tongluo therapy showed optimal clinical efficacy and safety. However, further rational experiments are needed to validate the above conclusions.
截至目前，尚无全面的荟萃分析评估解毒通络疗法对糖尿病肾病肾脏保护作用的有效性和安全性。本荟萃分析填补了这一知识空白。我们对包括中国知网、万方、PubMed和Web of Science在内的数据库进行了广泛检索。选择的依据是常规治疗，包括糖尿病肾病的信息与教育、血糖、高血压控制方法以及生活方式。对照组由常规西药或中成药组成，实验组由2003年至2023年间的解毒通络疗法对照试验（RCT）组成。使用R 4.1.0软件进行统计分析。共分析了来自19项RCT的1871例患者。荟萃分析结果显示，解毒通络疗法在提高临床疗效方面有效（OR = 2.47，95%CI[1.94, 3.15]， = 0%），并且这些试验在降低血肌酐（MD = -19.81，95%CI[-27.64, -11.97]， < 0.01）、血尿素氮（MD = -0.70，95%CI[-1.13, -0.27]， < 0.01）、尿白蛋白排泄率（MD = -29.97，95%CI[-37.33, -22.61]， < 0.01）、空腹血糖（MD = -0.85，95%CI[-1.22, -0.47]， < 0.01）以及特定药物安全性（OR = 0.75，95%CI[0.27, 2.11]）方面更有效。对于治疗糖尿病肾病，基于中医的解毒通络疗法显示出最佳的临床疗效和安全性。然而，需要进一步合理的实验来验证上述结论。
